Paraneoplastic neurological syndromes are a rare group of disorders that occur in 1 -2 % of people with malignancy. They are usually caused by an immune response, triggered by and directed against a tumour, that cross-reacts with protein expressed by the peripheral or central nervous system. Any part of the nervous system can be affected and patients often develop severe and permanent disability. Diagnosis can be difficult as in two-thirds of patients the neurological problems appear up to 5 years before the tumour manifests. However, certain of these syndromes are often associated with specific serum autoantibodies that can be useful both in diagnosis of the neurological syndrome and in focusing the search for a particular tumour. Thus, these antibodies can allow earlier identification and treatment of cancer and, potentially, a reduction in morbidity and mortality. It was only in the 1980s that the first onconeural autoantibodies were characterized and their associations with clinical syndromes and tumours defined. Further antibodies have been isolated over the past 20 years and novel pathogenic mechanisms for several syndromes have been recognized. For example, voltage-gate ion channels seem to be a common target for autoantibodies involved in peripheral nerve diseases such as the Lambert-Eaton myasthenic syndrome and neuromyotonla (Isaacs' syndrome). However, the place of most paraneoplastic antibodies in the pathogenesis of ce'ntral syndromes is yet to be fully elucidated.
Paraneoplastic neurological syndromes (PNS) are remote, non-metastatic complications oftumours (1). Although these syndromes are rare, occurring in about 1-2% of patients with neoplasia, they can involve any central or peripheral nervous structure and can cause severe and permanent disability (2) . Particular PNS are associated with certain tumour types, the commonest of which are small cell lung cancer (SCLC) and breast and gynaecological neoplasms. PNS often predate by several years the diagnosis of the underlying neoplasm. However, they can also manifest after the diagnosis ofcancer has been made, and sometimes appear during tumour remission. The majority of PNS have a sub acute onset and an aggressive course. In most patients, the nadir occurs within weeks and reaches a plateau, leaving the majority of individuals with severe disability (3) . The finding of a well characterized onconeural antibody in serum, and sometimes cerebrrospinal fluid (CSF), along with CSF inflammatory markers such as raised IgG or oligoclonal bands should instigate a search for an associated malignancy. Recent evidence suggests that whole-body positron emission tomography with f1uorodeoxyglucose is the most sensitive form of imaging for the early detection of many tumours in PNS (3a) .
The molecular mechanisms underlying many NPS are unknown (4) . One hypothesis, first suggested by Russell (5) , is that most paraneoplastic disorders result from an immunological response triggered by a tumour antigen that cross reacts, with an antigen expressed by the nervous system. Wilkinson demonstrated antibodies against neuronal tissue in the serum of patients with sensory neuropathy and bronchial carcinoma (6) . Successively, other researchers using immunological methods have isolated antibodies in patients' sera associated with a variety of different tumours (7) (8) . The immunological hypothesis was further supported by the finding of serum anti voltage-gate calcium channels antibodies (VGCC) in patients with the Lambert-Eaton myasthenic syndrome (LEMS) (9) . Since then, autoantibodies that target other neuronal ion channels have been demonstrated in several peripheral PNS, thus raising the possibility that ion channels may also be important target antigens in central syndromes (10) . The relative roles of humorally mediated immunity and cellular immunity in PNS are unresolved (II). The mainstay of therapy is the treatment of tumour and of appropriate immunomodulatory therapy for neurological manifestations. Useful therapies may include steroids, intravenous immunoglobulin and plasma exchange, with/without protein A columns. (12) .
Here we discuss the main PNS with particular emphasis on those that affect the central nervous system (CNS; Tab. I).
PNS OF THE CENTRAL NERVOUS SYSTEM
Paraneoplastic encephalomyelitis (PEM) Following work by Denny-Brown (13), Henson and co-workers (14) introduced the term "encephalomyelitis with carcinoma" to describe the clinical syndromes seen in cancer patients with signs of damage to more than one region of the nervous system, including the cortex, brainstem, spinal cord, and dorsal root ganglia. In a clinicopathological review of 69 patients, they found that paraneoplastic encephalomyelitis and sensory neuro-pathy (PEM/SN) frequently occur together, and that the most commonly associated neoplasm was SCLC (75%). PEM is a heterogeneous clinical syndrome with a wide variety of presentations (15) (16) .
The classic immunological feature of PEM/ SN is the presence of anti-Hu antibody, also called type 1 antineuronal autoantibody (ANNA-I) (17) (18) (19) . Using indirect immunofluorescence and Western blotting (WB), Graus demonstrated an antibody that reacted with neuronal antigens. It was named anti-Hu after the initials of the patient in which it was first detected. Anti-Hu is a polyclonal complement binding IgG, mainly of the IgG 1 subclass, that reacts with an antigen present in the nucleus of both neurones and SCLC cells (20) . On indirect immunohistochemistry, there is a distinct pattern of staining with strong binding to the nucleus with sparing of the nucleolus of all neurones of the central and peripheral nervous system ( Fig. I ) . WB shows triple bands in the 38-40 kD region.
Four Hu antigens have been cloned and isolated: HuD, HuC, Hel-Nl and Hel-N2. They are members of a family of human neuronal RNA-binding proteins, homologous to the Drosophila embryonic lethal abnormal visual protein (ELAV), which is involved in the normal development of the fly nervous system. They contain three RNA-binding domains and bind to the AU-rich 3' -untranslated elements of m-RNA encoding proteins, which seem to play an important role in cell proliferation and differentiation (21) . HuD, Hel-N I and N2 are all expressed by SCLC cells (22) . These findings support the theory that expression of one or more of the Hu antigens by tumour cells triggers an immune response cross reacting with neurone that results in neurological dysfunction (23) .
Some patients with PEM have autoantibodies with different immunoreactivity (Tab.!). These include antibodies found in patients with breast tumours that bind to the synaptic vesicle-associated protein amphiphysin and anti-CV2 or anti-collapsin response mediator potein (CRMP) antibodies associated with SCLC that are directed against a set of 62 to 66 kD proteins expressed in neurones and oligodendrocytes (24) (25) .
Anti-Mal antibodies are directed against a 37-kD neuronal protein and can be found in patients with carcinoma of breast, colon, lung or parotid gland (26) . Antibodies called anti-Ta or anti-Ma2 react with a 40-kD neuronal protein and seem to be highly specific for the limbic and/or brainstem encephalitis variants of PEM and particularly associated with testicular cancer, either seminoma or nonseminomatous germ-cell tumours (27) (28) .
Thus, PEM is immunologically as wel1 as c1inical1y heterogeneous.
Paraneoplastic cerebellardegeneration (PCD)
First described by Brouwer (29) , and subsequently by Greenfield (30) , cerebel1arcortical degeneration or paraneoplastic cerebellar degeneration (PCD) is pathological1y distinct from inflammatory NPS. The association between PCD and cancer was recognised in 1951 by Brain who also described the clinical and pathological features (31) . In 1976, Trotter reported a serum antibody against Purkinje cells in a patient with PCD associated with Hodgkin's disease, subsequently identified as anti-Tr antibody by Graus (32) (33) . Greenlee and Brashear in 1983 described circulating autoantibodies that bound to a cytoplasmic antigen in Purkinje cell (34) . They named the antibody anti-Y0 (35) , now also cal1ed Purkinje cytoplasm antibody-l (PCA-I) (18) .
Anti-Yo PCD usual1y occurs in women with breast or ovarian neoplasms and can occur up 15 months before the tumour is detected. The onset is typically subacute (over weeks to months) and is characterized by pancerebellar disfunction manifesting as truncal and limb ataxia, slurred speech and nystagmus (36) .
The typical immunological feature of PCD'is the presence of anti-Yo or PCA-I antibody which is a polyclonal complement fixing IgG. On indirect immunohistochemistry, it produces a coarse granular staining of Purkinje cell cytoplasm dendrites (37) ( Fig.2 ). On WB with cerebel1ar protein extracts, the antibody produces two bands at 32-34 kD and 62-64 kD [38] . The genes encoding the 34 kD and 62 kD Yo antigens have been cloned. The gene products are called cerebellar degeneration related proteins CDRI (CDR34) and CDR2 (CDR62). Two other antigens, a 58 kD (CZF) and a 52 kD (PCA-AA) protein, have been reported (39) (40) .
Anti-Tr antibody is also associated with PCD in patients with Hodgkin's lymphoma. This is an IgG antibody that labels the cytoplasm ofPurkinje cel1s and molecular layer neurones in a characteristic dotted pattern, which suggests immunoreactivity to dendritic spines. This antibody is not detectable by immunoblots (33) .
Another paraneoplastic IgG antibody cal1ed PCA-2, which occurs with PCD, binds to cerebel1ar Purkinje cell bodies and dendrites, neurones in the internal granular layer and dentate nucleus, and neuronal elements in the gut and kidney. On WB, it binds to a 280 kD protein, possibly a calcium channel. This antibody is associated with SCLC (41) .
Two other antibodies have been described associated with PCD: anti-mGluRI and ANNA-3. Anti-mGluR I reacts against cytoplasm ofPurkinje and brush cel1sand climbing fibres and is associated with Hodgkin's lymphoma (42) . ANNA-3 binds nuclei of cerebel1ar Purkinje neurons and to renal glomerular podocytes. It recognises a 170 kD antigen in cerebellum and SCLC (43) .
Paraneoplastic Opsoclonus-Myoclonus (POM)
Opsoclonus is characterized by random chaotic ocular movements that persist during eye closure and sleep (44) . Myoclonus is a shock-like contraction of a group of muscles, which is irregular in rhythm and amplitude, and asynchronous and asymmetrical in distribution. Trunk and gait ataxia often cause frequent fal1s and the myoclonus is mainly axial, affecting the trunk and head. paM can occur both in children, when it can be associated with neuroblastoma, and in adults with various different tumours, particularly SCLC and breast carcinoma (45) (46) .
The classic immunological feature the classic of paM patients is the presence of anti-R I antibody, also called ANNA-2 (47) . It binds to the nuclei and cytoplasm of all CNS, but not peripheral, neurones and labels proteins of 55 kD and, in some cases, 70 to 80 kD on WB. This multiplicity of protein binding suggests that paM is linked with different members of a protein family (48) . The genes that encode two Ri proteins have been cloned and are cal1ed Noval and 2 (49) . These proteins share sequence homology with a group of nuclear RNA-binding proteins believed to be involved in the regulation of m-RNA splicing (50) .
Paraneoplastic retinal degeneration or carcinoma associated retinopathy (CAR)
Since its first description in 1976, paraneoplastic retinal degeneration -or carcinoma associated retinopathy (CAR) -has become increasingly recognized, usual1y in association with SCLC (51) and circulating retinal antibodies (52) . Patients often develop dimming or blurring of vision up to 2 years before the diagnosis of cancer. Symptoms are usually bilateral, but can be asymmetrical. Night blindness is common and can be the initial complaint. It generally worsens over weeks to months and results in severe visual loss (53) .
The commonest retinal antibodies are polyclonal IgG CAR antibodies. On immunohistochemistry, they stain the inner and outer segment layers of the retina and, to a lesser degree, the inner nuclear layer. On WB using retinal extracts, the antibodies bind to the 23 kD calcium-binding protein recoverin, which plays a role in light transduction. Recoverin is a member ofEF-hand, calmodulin family (54) . Many patients have other identifiable retinal antibodies distinct from recoverin, such as retinal enolase or retinal S-antigen (55), especially ifSCLC is present (56) .
Stiff man plus syndrome
The first description of stiff man syndrome was by Moersch and Woltmann in 1956 (57) . It is characterized by paraspinal and abdominal muscle rigidity, which often cause an exaggerated lumbar lordosis, with superimposed muscle spasms that are triggered by movement, emotional upset, sensory stimulation, or sudden noise. Severe variants have been called stiff man plus. These are characterized by subacute onset, progressive encephalomyelitis causing widespread rigidity, myoclonus, and muscle spasms in addition to long tract and brainstem problems (58) . Patients often have serum and CSF IgG antibodies to the synaptic vesicle associated 128 kD protein amphiphysin. On immunohistochemistry, anti-amphiphysin antibodies stain the neuropil and, to a lesser degree, the cytoplasm of large neurones in the cerebral and cerebellar cortices. Breast carcinoma and SCLC are the commonest associated tumours, although a few patients have had a colon adenocarcinoma or Hodgkin's lymphoma (59) .
PNS of the peripheral nervous system
The reported incidence of paraneoplastic polyneuropathy among cancer patients ranges from 10% in clinical studies up to 40% when electrophysiological examinations are also performed (60) . Paraneoplastic neuropathies have been variously classified according to rapidity of onset, clinical severity, the presumed site of pathology, or some combination of these factors. As in all PNS, a neuropathy can only be considered as paraneoplastic when other possible causes are excluded and ideally when cancer associatedimmunological mechanisms are detected (61) . Paraneoplastic neuropathies usually present before the tumour and can be more debilitating than the malignancy itself. There is, as yet, an unexplained majority of women among these patients.
Subacute sensory neuronpathy (SSN)
SSN is the most common paraneoplastic neuronpathy and often results from damage to the dorsal root ganglia (62) . The first description of SSN as a complication of lung cancer was by Denny-Brown in 1948 (13) . In 1965, Wilkinson detected antibodies in patients with neuropathies and cancer (63) . SSN can present with PEM or in isolation.
SSN usually has an abrupt onset, over hours to days and involves all sensory modalities.
The commonest associated tumour is SCLC and the commonest antibody is anti-Hu (64).
Myasthenia Gravis (MG)
MG is the best known and best characterized autoimmune disease ofthe neuromuscularjunction. About 10% of MG patients have a thymoma, usual1y a tumour of the thymic epithelial cel1s. These patients almost always have detectable antibodies to muscle nicotinic acetylcholine receptors (AChR). About 90% ofthymoma patients also have antibodies to various striated muscle determinants such as ryanodine receptors and titin (65) . The clinical hallmark of MG is fluctuating weakness of voluntary muscles. MG typical1y presents with asymmetrical ptosis and diplopia. The presence of serum AChR antibodies confirms the diagnosis of MG (66) .
Lambert-Eaton myasthenic syndrome (LEMS)
LEMS, like MG, is an autoantibody-mediated channelopathy of the neuromuscular junction. However, in LEMS, the main antigenic targets are presynaptic voltage-gated calcium channels (VGCC) (67) . Although LEMS can occur spontaneously, about 67% of patients have an associated tumour -most commonly SCLC or more rarely lymphoma, adenocarcinoma, or thymoma (68) . It is thought that tumour cell VGCCs trigger the production of autoantibodies that crossreact with antigenical1y similar nerve channels to AUTO produce channel downregulation and a reduction in acetylcholine release from the nerve terminal. LEMS usually manifests as subacute onset, weakness of the proximal muscles. Ptosis, diplopia, and bulbar and respiratory muscle weakness can occur, but are much less common than in MG. Muscle strength usually increases transiently during the first few seconds of maximal voluntary contraction (augmentation), then fatigues.
Serum IgG antibodies to the P/Q subtype of VGCCs are detected in up to 90% of patients with paraneoplastic LEMS (69).
Acquired neuromyotonia (Isaacs' syndrome)
Acquired neurornyotonia (NMT) is characterized by spontaneous peripheral nerve hyperexcitability that usually manifests as generalized, continuous muscle overactivity causing twitching, cramps, and stiffness (70) . NMTpatients have serum IgG antibodies to voltage-gated potassium channels (VGKC). These antibodies increase nerve excitability both in situ and in vitro [71] [72] . Up to 20% of NWT patients have a tumour, usually thymoma. SCLC, various adenocarcinomas and Hodgkin's lyphoma are also reported.
CONCLUSION
It is crucial that PNS and their underlying tumours are diagnosed quickly to maximize the chance of successful treatment. This can be difficult as PNS are clinically and immunologically heterogeneous. Serum anti neuronal antibodies can often help. However, there are limitations to their usefulness. Many patients with CNS PNS do not have detectable, well-characterized antibodies or they have atypical and uncharacterized antibodies, which may not be picked up by commercially available assays (Fig.3 ). In addition, certain antibodies can be present at low titres in patients with tumours but without any neurological problems. Moreover, a few patients with neurological problems have high titres of serum anti-neuronal antibodies, but never develop a demonstrable tumour. These findings demonstrate that large epidemiological studies are required to improve our knowledge of the sensitivity and specificity of both classic and atypical antibodies in diagnosis ofPNS. In parallel with this, research on the molecular mechanisms that produce PNS will allow more specific and effective treatments to be developed.
